Validation of in Vitro Method for Anti-MCPyV Immunotherapy on Patients With Merkel Cell Carcinoma of Skin
Status: Recruiting
Location: See location...
Study Type: Observational
SUMMARY
The aim of the study is to test and validate in vitro a cell therapy approach for MCPyV+ Merkel Cell Carcinoma patients.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Patients \>= 18 years old;
• Diagnosed with Merkel cell carcinoma of skin, ongoing for local treatment, systemic treatment, complementary treatment or an active follow-up;
• Informed for the study and no-opposed for participation;
• Affiliated with a social security scheme or in an equivalent situation.
Locations
Other Locations
France
Dermato-oncology Department, Ambroise Paré Hospital, APHP
RECRUITING
Boulogne-billancourt
Contact Information
Primary
Astrid Blom, MD
astrid.blom@aphp.fr
+33 (01) 49 09 44 82
Backup
Yassine Taoufik, MD, PhD
yassine.taoufik@aphp.fr
Time Frame
Start Date: 2025-05-27
Estimated Completion Date: 2027-05
Participants
Target number of participants: 15
Related Therapeutic Areas
Sponsors
Collaborators: Institut National de la Santé Et de la Recherche Médicale, France
Leads: Assistance Publique - Hôpitaux de Paris